Skip to main content
Clinical Trials/NCT06502769
NCT06502769
Not yet recruiting
Not Applicable

Efficacy of Therapeutic Exercise and Pain Neurophysiology Education in Temporomandibular Disorders: a Single-blind Randomized Controlled Trial

University of Alcala1 site in 1 country36 target enrollmentSeptember 1, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Temporomandibular Disorder
Sponsor
University of Alcala
Enrollment
36
Locations
1
Primary Endpoint
Pain intensity
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

The aim of this study is to compare the effects in pain of two different treatments in pacients with temporomandibular disorders (TMD). One group will receive isolated therapeutic exercise (TE) and the other will receive TE combined with pain neurophysiology education (PNE). The hypothesis of this study is that the PNE+TE group will obtain superior therapeutic results than an isolated TE program.

Detailed Description

Objective: To evaluate the differences in pain intensity by performing isolated therapeutic exercise (TE) versus performing the same exercise combined with pain neurophysiology education (PNE) in patients with temporomandibular disorders (TMD). Design: Single-blind randomized controlled trial. Setting: Faculty of Physical Therapy of Alcalá de Henares. Participants: Subjects with TMD lasting more than 6 months (N= 36). Interventions: Participants will be randomly assigned to receive a TE program consisting of stretching, coordination and strengthening exercises (n= 18) or the same TE program in addition to a PNE program (n= 18), performed in two sessions of 40 minutes in groups of 6 participants. The intervention will last 12 weeks, where all participants must complete the exercise program daily, one year later they will be evaluated again. Main outcome measures: The primary outcome will be pain intensity through the visual analogue scale (VAS) which will be completed at baseline, immediately after treatment, at 4 and 12 weeks and one year after treatment. Secondary outcome measures include pain-free mouth opening, Craniofacial Pain and Disability Inventory (CF-PDI), Pain Catastrophizing Scale (PCS), Tampa Scale for Kinesiophobia for Temporomandibular Disorders (TSK-11), pressure pain thresholds (PPT) and Patient Global Impression of Change (PGIC). They will be recorded through blinded assessments performed by 2 physiotherapists at baseline, immediately after treatment, 4 and 12 weeks after treatment. Student's t test will be used to determine differences between group interventions.

Registry
clinicaltrials.gov
Start Date
September 1, 2024
End Date
September 30, 2026
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
University of Alcala
Responsible Party
Principal Investigator
Principal Investigator

María Teresa Ortiz Moreno

MSc

University of Alcala

Eligibility Criteria

Inclusion Criteria

  • Over 18 years of age
  • Limitation of mouth opening and/or jaw pain lasting more than 6 months
  • Being able to understand the objective and carry out the study procedures
  • Sign the informed consent.

Exclusion Criteria

  • Suffer from any underlying disease
  • Pain due to tumors or infections, metastases, osteoporosis, inflammatory arthritis or fractures
  • Be receiving any other treatment for TMD or consuming some type of substance that alters muscle tone.
  • Patients with myopathies, diseases of the Peripheral Nervous System, mental disorders diagnosed by a doctor
  • Inability to collaborate
  • Any other situation in which the evaluation could be altered.

Outcomes

Primary Outcomes

Pain intensity

Time Frame: The scale will be passed at baseline, immediately after treatment, at 4 and 12 weeks and one year after treatment.

The intensity of pain will be evaluated using the Visual Analogue Scale that is represented by a 10cm line where the left end indicates "no pain" and the right end indicates "maximum pain".

Secondary Outcomes

  • Mouth opening without pain(at baseline, immediately after treatment, 4 and 12 weeks after treatment.)
  • Orofacial disability and pain(at baseline, immediately after treatment, 4 and 12 weeks after treatment.)
  • Kinesiophobia(at baseline, immediately after treatment, 4 and 12 weeks after treatment.)
  • Pressure pain thresholds(at baseline, immediately after treatment, 4 and 12 weeks after treatment.)
  • Catastrophism(at baseline, immediately after treatment, 4 and 12 weeks after treatment.)
  • Self-Perception of Improvement(at baseline, immediately after treatment, 4 and 12 weeks after treatment.)

Study Sites (1)

Loading locations...

Similar Trials